Tag Archives: pharmacy

Germany will speak with Biden’s team to secure a change to vaccine distribution – POLITICO | Instant News

The German government “wants to hold talks” with the new US government to agree to a change in US policy prioritizing local supplies of the coronavirus vaccine at US production facilities, according to documents from the German health ministry.

In a lengthy document published Tuesday responding to inquiries from the German Social Democrats, the health ministry explained why the US could secure an additional supply of BioNTech / Pfizer vaccine for a certain date, whereas an increase in EU supply would come “in 2021.”

The health ministry stated that an executive order from the US president stated that production facilities in the country were “encouraged to provide vaccines for supply in the US”. This means that BioNTech / Pfizer vaccine production sites in Europe, as well as Moderna vaccines, need to supply worldwide, apart from Europe.

“The company as well as the federal government would like to hold talks with the new US government to reach an adjustment,” wrote the health ministry.

The document also discusses the bilateral agreement Germany has with BioNTech / Pfizer – something related to that The commission has let Germany escape, although it appears to be at odds with the block’s efforts to develop an integrated vaccine strategy.

The problem, the health ministry explained, was the funds BioNTech received from the German ministry of education and research. This cash means BioNTech will have to provide a portion of the vaccine to Germany. As a result, the health ministry had to issue a pre-contracted intention letter in the form of a memorandum of understanding on September 8 for an additional 30 million doses of vaccine, the health ministry wrote.


image source

Pediatric Consumer Health in Germany until 2024 | Instant News

Dublin, January 18, 2021 (GLOBE NEWSWIRE) – The “Pediatric Consumer Health in Germany” reports have been added to ResearchAndMarkets.com offerings.

Similar to its impact on adult analgesics and vitamins and dietary supplements, the emergence of COVID-19 has resulted in an accumulation of cough / cold medicines for children in the short term in addition to a significant increase in demand for pediatric vitamins and dietary supplements. While the rate of the spike may not be as obvious for the pediatric category, the impact can be seen for major contributing categories including pediatric acetaminophen, and vitamins and dietary supplements.

The Pediatric Consumer Health Report in Germany offers a comprehensive guide to market size and shape at the national level. It provides the latest 2015-2019 retail sales data, enabling you to identify sectors that are driving growth. The forecasts through 2024 illustrate how the market will change.

Product coverage: Diaper Rash (Diaper) Treatment, Pediatric Analgesics, Cough Children, Colds and Allergy Treatment, Pediatric Dermatology, Pediatric Digestive Medicine, Pediatric Vitamins and Food Supplements.

Data coverage: Market size (history and forecast), company shares, brand shares, and distribution data.

Main report benefits:

  • Get a detailed overview of the Pediatric Consumer Health market;
  • Define sectors of growth and identify factors driving change;
  • Understand the competitive environment, major market players and leading brands;
  • Use the five-year forecast to assess how the market is expected to develop.

Main Topics Covered:



  • COVID-19 contributes to the growth of pediatric consumer health by 2020
  • Pediatric vitamins and dietary supplements are benefiting from the COVID-19 outbreak
  • Multinational companies maintain an important presence in the competitive landscape


  • Good growth rate to continue
  • Natural product trends are more prominent in the health of child consumers
  • Players are showing greater interest in the health of child consumers because of the potential for further growth


  • Table 1 Sales of Pediatric Consumer Health by Category: Value 2015-2020
  • Table 2 Pediatric Consumer Health Sales by Category:% Growth Value 2015-2020
  • Table 3 Sales of Pediatric Vitamins and Dietary Supplements by Type:% Value 2015-2020
  • Table 4 Pediatric Consumer Health NBO Company Shares:% Value 2016-2020
  • Table 5 Share of Child Consumer Health LBN Brands:% Value 2017-2020
  • Table 6 Pediatric Consumer Health Sales Forecast by Category: 2020-2025 Value
  • Table 7 Estimated Pediatric Consumer Health Sales by Category:% Growth Value 2020-2025


  • COVID-19 has an impact on consumer health
  • Impact of COVID-19 countries
  • Company response
  • Retail shift
  • What’s next for consumer health?


  • Table 8 Consumer Expenditures on Health Goods and Medical Services: Value 2015-2020
  • Table 9 Life Expectancy at Birth 2015-2020


  • Table 10 Consumer Health Sales by Category: Value 2015-2020
  • Table 11 Consumer Health Sales by Category:% Value Growth 2015-2020
  • Table 12 Share of Consumer Health in NBO Companies:% Value 2016-2020
  • Table 13 Share of LBN Consumer Health Brands:% Value 2017-2020
  • Table 14 Private Label Penetration in Consumer Health by Category:% Value 2015-2020
  • Table 15 Distribution of Consumer Health by Format:% Value 2015-2020
  • Table 16 Distribution of Consumer Health by Format and Category:% 2020 Value
  • Table 17 Forecast of Consumer Health Sales by Category: 2020-2025 Value
  • Table 18 Forecast of Consumer Health Sales by Category:% Value Growth 2020-2025


  • OTC registration and classification
  • Registration and classification of vitamins and dietary supplements
  • Self-medication / self-care and preventive medicine
  • Switch
  • OTC 1 Overview: Switching 2019-2020



For more information on this report visit https://www.researchandmarkets.com/r/di0tvz

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source of international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Research and Markets also offers Custom Research services provide focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


image source

Time Pharmacy | Practical Information for Current Pharmacists | Instant News

There is particular interest in monoclonal antibody agents to determine whether their immune-suppressing effects can reduce the immediate and long-term effects of COVID-19.

According to research conducted at Rush University Medical Center, opioid use can increase a patient’s risk of developing pancreatic cancer.

COVID-19 has been found in the post-mortem brain.

Moderna, Inc has also announced a provisional authorization for the COVID-19 vaccine in Switzerland.

The current study provided a characterization of a lipid-rich necrotic core, a dangerous type of coronary plaque composed of dead cells and cell debris that is prone to rupture, which can lead to a heart attack or stroke.

Some important things for maintaining a woman’s sexual function include positive sexual experiences, attitudes about sex, body image, and intimacy in relationships.

Experts in NET management discuss how the medicinal landscape has evolved.

The study authors said their main hypothesis for a higher prevalence of olfactory dysfunction in mild cases of COVID-19 was based on differences in immune response to infection.

Verdinexor tablets are only available by prescription, and can be given at home.

The FDA has provided a fast-track designation for cavrotolimod (AST-008) for use in combination with PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma.

The Association of Community Cancer Centers offers a virtual learning suite.

Amneal Pharmaceuticals, Inc announced that it has received approval of an additional strength of 500 mg for its New Abbreviated Drug Application from the FDA for Abiraterone Acetate tablets.


image source

Brazil Receives China’s Covid-19 Vaccine When Cases Soar | Instant News

SÃO PAULO – The government of Brazilian President Jair Bolsonaro has backed away from its criticism of the Chinese vaccine and agreed to purchase up to 100 million doses of injections developed by China’s Sinovac, as Latin America faces a post-holiday spike in Covid-19 cases.

Bolsonaro, a former army captain who followed President Trump’s lead in attacking China, has long discredited the Sinovac vaccine, which had been tested by the state’s research center in a partnership supported by his political rival, São Paulo’s Governor João Doria. Only two months ago, Mr. Bolsonaro told supporters that the CoronaVac vaccine could kill or incapacitate them, without providing evidence, and refused to buy it.

But over the past few months, a Chinese vaccine has emerged as one of Brazil’s best bets against a pandemic that has claimed the lives of more than 200,000 people here, second only to the US.

The Health Ministry said late Thursday that it had signed a contract with the Butantan Institute, the São Paulo state research center that has tested and manufactured CoronaVac, to purchase 46 million doses. The ministry said it had the option to buy another 54 million, enough to immunize 50 million people with two dose shots, or about a quarter of Brazil’s population.

Latin America is racing to secure doses as cases surge across the region. Hundreds of thousands of people have tested positive in Latin America this week, after many defied government warnings and held large family gatherings over busy holidays and beaches in the early Southern Hemisphere summer. With only 8% of the world’s population, Latin America has accounted for nearly 30% of deaths from Covid-19.


image source

Roche Actemra, Kevzara Regeneron wins UK support in COVID-19 after research shows 24% reduction in risk of death | Instant News

The question of whether seriously ill COVID-19 patients could benefit from anti-inflammatories such as Roche Actemra and Sanofi and Regeneron’s Kevzara has weighed heavily on practitioners in the United States thanks to conflicting clinical trial results.

In contrast, the UK has reached definite answers for both drugs, both of which are IL-6 inhibitors: These drugs significantly reduce the risk of death in COVID-19 patients requiring intensive care, and they must be used to relieve the stress that hospitals face when this is because the coronavirus pandemic continues to escalate, the country’s National Institute of Health Research (NIHR) said Thursday.

The recommendations came after data from an NIHR-sponsored study showed that Actemra and Kevzara could cut hospital stay for COVID-19 patients in intensive care by 10 days and could reduce the risk of death by 24% in patients receiving one of the drugs. in the day of entry. The findings prompted the UK government to recommend to the National Health Service (NHS) that IL-6 blockers be launched for the treatment of COVID-19.

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: Key Educational Event Focusing on Decentralized Clinical Trials

In this virtualized environment, we will look at current and future trends for virtual trials underway, delving into the many ways companies can improve patient engagement and trial behavior to improve retention with a focus on emerging technologies and harmonized data access across clinical trial system.

“We have worked swiftly to ensure this care is available to NHS patients without delay,” UK Secretary of Health and Social Care Matt Hancock said in a statement. statement, adding that the trial results mark “an important development in finding a way out of this pandemic.”

Trial data, which have not been peer reviewed, are published (PDF) on the preprint site medRxiv.

RELATED: Does Roche’s Actemra work in COVID-19? The new study once again paints a mixed picture

Actemra and Kevzara may have received acceptance in the UK, but their paths to success in COVID-19 in the US are less clear. An observational study published last fall in JAMA Internal Medicine reported that Actemra was associated with a 29% reduced risk of death in critically ill COVID-19 patients.

But randomized clinical trials of Roche’s drug in Italy concluded that it did not result in improvements in disease progression or mortality. A similar trial in France reported that Actemra’s effectiveness in moderate to severe COVID-19 patients was mixed.

As for Sanofi and Regeneron, they are also struggling to make a strong case for Kevzara in COVID-19. During the summer, firm turn off drug trials after finding it did not help patients in ventilating. Then they released data from a Kevzara study in several countries showing that the drug failed to produce a statistically significant difference in length of hospital stay or symptom improvement.

RELATED: After the other Kevzara failed COVID-19, Sanofi and Regeneron turned their attention elsewhere

The potential benefits of IL-6 inhibitors in coronavirus patients were recognized by scientists early on during the pandemic. When the immune system fights off viruses, often it releases a flood of inflammatory molecules that can cause organ failure. Controlling IL-6 seems like an immediate way to control that reaction, so many experts remain confused as to why Actemra and Kevzara, both approved to treat rheumatoid arthritis, have not consistently performed well in COVID-19 trials.

Roche continues to study Actemra on COVID-19, launching a clinical trial last summer of the drug in combination with Gilead’s Veklury (remdesivir). The study is ongoing and recruiting patients in 73 hospitals worldwide.


image source